EAM
IMMX icon

Eventide Asset Management’s Immix Biopharma IMMX Stock Holding History

Eventide Asset Management’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.2M Hold
2,549,019
– – 0.38% 90
2025
Q4 		$13.3M Buy
+2,549,019
New +$10.5M 0.21% 127

Other funds holding IMMX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Eventide Asset Management's IMMX Position: Q1 2026 in Review

Eventide Asset Management held its Immix Biopharma (IMMX) position steady in Q1 2026 at 2,549,019 shares worth $23.2M. The position accounts for 0.38% of the portfolio, ranked #90.

Eventide Asset Management first reported a position in IMMX in Q4 2025 and has held it in 2 quarters since. 77 funds tracked by Wall St. Rank hold IMMX as of Q1 2026.

  • Eventide Asset Management held 2,549,019 shares of Immix Biopharma worth $23.2M as of Q1 2026.
  • Eventide Asset Management left its Immix Biopharma share count unchanged in Q1 2026.
  • Immix Biopharma made up 0.38% of Eventide Asset Management's portfolio in Q1 2026, its #90 holding.
  • Eventide Asset Management first reported a position in Immix Biopharma in Q4 2025 and has held it in 2 quarters since.
  • 77 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2026.

Based on Eventide Asset Management's 13F filing for Q1 2026, filed 15 May 2026.